E.U. Court Favors Generic Makers With Ruling Against Novartis
Novartis had challenged the marketing authorization given by the Medicines Control Agency (now the Medicines and Healthcare Regulatory Agency) to the generic company SangStat for a product that competed with certain Novartis transplant surgery drugs.
SangStat, now owned by Genzyme Corp., had relied on Novartis's clinical data for a second formulation of the product,...
To view the full article, register now.